Latest news

• BMS and 2seventy bio announce positive results for multiple myeloma treatment

  The results show that Abecma ‘significantly improves’ progression-free survival in relapsed and refractory multiple myeloma. ... Treatment with Abecma also showed an improvement in the key secondary endpoint of overall response rate compared to

• BMS and 2seventy bio move away from CAR-T programme

  The two companies will focus their efforts on furthering the growing success of BMS’ therapy Abecma. ... Abecma, approved in March 2021 as the first BCMA CAR-T programme, is a fourth-line or later treatment for patients with multiple myeloma.

• bluebird bio splits to create new oncology firm 2seventy bio

  Its portfolio includes a development and commercialisation deal with Bristol Myers Squibb for Abecma (idecabtagene vicleucel), its B-cell maturation antigen (BCMA)-directed CAR T-cell therapy approved by the Food

• BMS reports strong growth as its Q3 results beat predictions

  The company’s CAR-T cancer drugs posted strong growth: Abecma (idecabtagene vicleucel), which launched in May as the first cell-based gene therapy for multiple myeloma, had $71m in sales,

• EC approves BMS cell therapy for multiple myeloma

  The approval of Abecma is based on “rapid, deep and durable” trial responses. ... BMS has raised the possibility of a European-based manufacturing facility in Leiden, Netherlands to help make Abecma commercially available to patients in the EU.